Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.

J Clin Oncol · 2023 · PMC10713185 · PMID 37713657

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

EQ-5D UI scores showed a trend toward improvement from baseline over time with nivolumab plus chemotherapy but showed minimal changes from baseline with chemotherapy (Fig 1 D).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.